Hunan Jingfeng Pharmaceutical (000908) — Strategic Asset Allocation Index
Hunan Jingfeng Pharmaceutical (000908) has a Strategic Asset Allocation Index of 278.6% as of September 2023. Strategic assets (PP&E of CN¥522.82 Million plus long-term investments of CN¥-) total CN¥522.82 Million, measured against net assets of CN¥187.65 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check how resilient are Hunan Jingfeng Pharmaceutical's assets to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Hunan Jingfeng Pharmaceutical Strategic Asset Allocation Index (2000–2022)
This chart shows how Hunan Jingfeng Pharmaceutical's Strategic Asset Allocation Index has evolved across 22 annual periods from 2000 to 2022. As of September 2023, the index stands at 278.6%, representing strategic assets of CN¥522.82 Million against net assets of CN¥187.65 Million CNY. See financial agility of Hunan Jingfeng Pharmaceutical to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Hunan Jingfeng Pharmaceutical (2000–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Hunan Jingfeng Pharmaceutical from 2000 to 2022, covering 22 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is Hunan Jingfeng Pharmaceutical worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 263.7% | CN¥566.42 Million | CN¥566.42 Million | CN¥- | CN¥214.83 Million | ▲ +42.1 pp |
| 2021 | 221.6% | CN¥726.10 Million | CN¥726.10 Million | CN¥- | CN¥327.73 Million | ▲ +62.7 pp |
| 2020 | 158.9% | CN¥1.01 Billion | CN¥1.01 Billion | CN¥- | CN¥638.18 Million | ▲ +95.4 pp |
| 2019 | 63.4% | CN¥1.23 Billion | CN¥1.23 Billion | CN¥- | CN¥1.94 Billion | ▲ +14.8 pp |
| 2018 | 48.7% | CN¥1.39 Billion | CN¥1.05 Billion | CN¥343.64 Million | CN¥2.86 Billion | ▲ +5.4 pp |
| 2017 | 43.3% | CN¥1.13 Billion | CN¥784.97 Million | CN¥340.28 Million | CN¥2.60 Billion | ▲ +9.3 pp |
| 2016 | 34.0% | CN¥888.29 Million | CN¥667.68 Million | CN¥220.60 Million | CN¥2.61 Billion | ▲ +2.0 pp |
| 2015 | 32.0% | CN¥719.73 Million | CN¥483.86 Million | CN¥235.86 Million | CN¥2.25 Billion | ▼ -2.9 pp |
| 2014 | 34.9% | CN¥347.39 Million | CN¥347.39 Million | CN¥- | CN¥994.04 Million | ▼ -2278.4 pp |
| 2013 | 2313.4% | CN¥122.81 Million | CN¥122.81 Million | CN¥- | CN¥5.31 Million | ▼ -18493.5 pp |
| 2011 | 20806.9% | CN¥164.54 Million | CN¥164.54 Million | CN¥- | CN¥790.82K | ▲ +20552.8 pp |
| 2010 | 254.1% | CN¥147.00 Million | CN¥147.00 Million | CN¥- | CN¥57.85 Million | ▲ +95.4 pp |
| 2009 | 158.8% | CN¥159.84 Million | CN¥159.84 Million | CN¥- | CN¥100.67 Million | ▲ +100.9 pp |
| 2008 | 57.9% | CN¥196.07 Million | CN¥196.07 Million | CN¥- | CN¥338.64 Million | ▼ -1.0 pp |
| 2007 | 58.9% | CN¥198.35 Million | CN¥198.35 Million | CN¥- | CN¥336.95 Million | ▼ -24.1 pp |
| 2006 | 83.0% | CN¥279.25 Million | CN¥279.25 Million | CN¥- | CN¥336.40 Million | ▼ -0.3 pp |
| 2005 | 83.3% | CN¥274.63 Million | CN¥274.63 Million | CN¥- | CN¥329.66 Million | ▲ +40.2 pp |
| 2004 | 43.1% | CN¥146.33 Million | CN¥146.33 Million | CN¥- | CN¥339.45 Million | ▲ +0.4 pp |
| 2003 | 42.7% | CN¥179.07 Million | CN¥179.07 Million | CN¥- | CN¥419.38 Million | ▲ +6.5 pp |
| 2002 | 36.2% | CN¥189.15 Million | CN¥189.15 Million | CN¥- | CN¥522.69 Million | ▲ +4.4 pp |
| 2001 | 31.8% | CN¥158.37 Million | CN¥158.37 Million | CN¥- | CN¥498.41 Million | ▲ +8.8 pp |
| 2000 | 23.0% | CN¥115.11 Million | CN¥115.11 Million | CN¥- | CN¥500.54 Million | — |